t
ValiRx Plc announced on June 9, 2025, that it will host a post-Results investor webinar. The webinar will feature CEO Mark Eccleston and is scheduled for Thursday, June 12, 2025, at 10am BST.
| Date | 9 Jun 2025 |
| Time | 10:57:09 |
| Category | Miscellaneous |
| ID | 0200M |
9 June 2025
ValiRx
("VAL" or the "Company")
ValiRx Investor Webinar
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to announce a post-Results webinar with CEO Mark Eccleston.
The webinar will be hosted live via our website on Thursday, 12 June 2025 at 10am BST, and we invite both existing and prospective investors to submit their questions in advance. You can do so from here: https://valirx.com/webinars/XyO1Xr-annual-results-fy2024
For further information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
https://valirx.com/link/lyapKP
|
|
ValiRx plc
Dr Mark Eccleston, CEO
|
Tel: +44 115 784 0025
|
|
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti
|
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0) 20 7186 9000 |
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director
|
+44 (0) 115 787 0206
|
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com